H.C. Wainwright Remains a Hold on BioMarin Pharmaceutical (BMRN)
H.C. Wainwright analyst Mitchell Kapoor reiterated a Hold rating on BioMarin Pharmaceutical today and set a price target of $55.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Kapoor covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Halozyme, and Summit Therapeutics. According to TipRanks, Kapoor has an average return of 11.7% and a 41.86% success rate on recommended stocks.
In addition to H.C. Wainwright, BioMarin Pharmaceutical also received a Hold from William Blair’s Sami Corwin in a report issued on February 24. However, on February 26, Canaccord Genuity maintained a Buy rating on BioMarin Pharmaceutical (NASDAQ: BMRN).
Based on BioMarin Pharmaceutical’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $874.57 million and a GAAP net loss of $46.57 million. In comparison, last year the company earned a revenue of $747.31 million and had a net profit of $124.94 million
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BMRN in relation to earlier this year. Last month, George Eric Davis, the EVP, CLO of BMRN sold 26,061.00 shares for a total of $1,599,102.96.
Read More on BMRN:
